NASDAQ:CHMA - Chiasma Stock Price, Price Target & More

$1.45 -0.07 (-4.61 %)
(As of 04/26/2018 09:30 AM ET)
Previous Close$1.52
Today's Range$1.40 - $1.55
52-Week Range$1.25 - $2.95
Volume50,900 shs
Average Volume53,586 shs
Market Capitalization$37.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99

About Chiasma (NASDAQ:CHMA)

Chiasma logoChiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts.

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CHMA
CUSIPN/A
Webwww.chiasmapharma.com
Phone617-928-5300

Debt

Debt-to-Equity RatioN/A
Current Ratio10.19%
Quick Ratio10.19%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.56 per share
Price / Book0.57

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-26,820,000.00
Net MarginsN/A
Return on Equity-36.33%
Return on Assets-32.42%

Miscellaneous

Employees16
Outstanding Shares24,380,000

How to Become a New Pot Stock Millionaire

Chiasma (NASDAQ:CHMA) Frequently Asked Questions

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How were Chiasma's earnings last quarter?

Chiasma Inc. (NASDAQ:CHMA) released its quarterly earnings data on Tuesday, March, 20th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.02. View Chiasma's Earnings History.

When is Chiasma's next earnings date?

Chiasma is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Chiasma.

Who are some of Chiasma's key competitors?

Who are Chiasma's key executives?

Chiasma's management team includes the folowing people:
  • Mr. Mark J. Fitzpatrick, Pres, CEO & Director (Age 55)
  • Mr. Drew Enamait, VP of Fin. & Admin. & Principal Accounting Officer (Age 44)
  • Mr. Steven Vickers, VP of Sales
  • Dr. Gary Patou M.D., Head of Clinical (Age 59)
  • Dr. William H. Ludlam M.D., Ph.D., Sr. VP of Clinical Devel. & Medical Affairs

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Has Chiasma been receiving favorable news coverage?

Press coverage about CHMA stock has been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chiasma earned a coverage optimism score of 0.15 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.34 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Chiasma?

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $1.45.

How big of a company is Chiasma?

Chiasma has a market capitalization of $37.19 million. Chiasma employs 16 workers across the globe.

How can I contact Chiasma?

Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]


MarketBeat Community Rating for Chiasma (CHMA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Chiasma (NASDAQ:CHMA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ASell
Consensus Rating Score: N/AN/AN/A1.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)		1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Chiasma (NASDAQ:CHMA) Consensus Price Target History

Price Target History for Chiasma (NASDAQ:CHMA)

Chiasma (NASDAQ:CHMA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2017BarclaysDowngradeEqual Weight -> UnderweightN/AView Rating Details
5/13/2016CowenReiterated RatingHoldN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Chiasma (NASDAQ:CHMA) Earnings History and Estimates Chart

Earnings by Quarter for Chiasma (NASDAQ:CHMA)

Chiasma (NASDAQ CHMA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018($0.36)N/AView Earnings Details
3/20/2018Q4 2017($0.23)($0.25)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.28)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.28)ViewN/AView Earnings Details
5/5/2017Q1 2017($0.23)($0.2880)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.59)($0.30)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.73)($0.35)ViewN/AView Earnings Details
8/10/2016Q2($0.6330)($0.83)ViewListenView Earnings Details
5/11/2016Q1($0.63)($0.71)ViewListenView Earnings Details
3/14/2016Q4($0.53)($0.61)ViewListenView Earnings Details
11/12/2015Q315($0.38)($0.46)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Chiasma (NASDAQ:CHMA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Chiasma (NASDAQ CHMA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 53.84%
Insider Trading History for Chiasma (NASDAQ:CHMA)
Institutional Ownership by Quarter for Chiasma (NASDAQ:CHMA)

Chiasma (NASDAQ CHMA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2018Roni MamlukDirectorSell2,389$1.53$3,655.172,389View SEC Filing  
12/18/2017Roni MamlukDirectorSell2,389$1.75$4,180.752,389View SEC Filing  
10/24/2017Roni MamlukDirectorSell2,389$2.27$5,423.032,389View SEC Filing  
9/21/2017Scott MinickDirectorBuy25,000$2.37$59,250.00View SEC Filing  
9/20/2017Scott MinickDirectorBuy15,000$2.38$35,700.00View SEC Filing  
7/21/2015Health Ventures Lp 7-MedMajor ShareholderBuy93,750$16.00$1,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Chiasma (NASDAQ CHMA) News Headlines

Source:
DateHeadline
Chiasma (CHMA) to Release Quarterly Earnings on ThursdayChiasma (CHMA) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - April 26 at 2:50 AM
ValuEngine Upgrades Chiasma (CHMA) to SellValuEngine Upgrades Chiasma (CHMA) to Sell
www.americanbankingnews.com - March 25 at 7:32 PM
FDA Nod For SGENs Adcetris, Antibe Therapeutics Soars On GI Data, CHMA EmpoweredFDA Nod For SGEN's Adcetris, Antibe Therapeutics Soars On GI Data, CHMA Empowered
www.finanznachrichten.de - March 21 at 10:52 AM
Chiasma (CHMA) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPSChiasma (CHMA) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - March 21 at 7:38 AM
Chiasma Reports Fourth Quarter and Year End 2017 ResultsChiasma Reports Fourth Quarter and Year End 2017 Results
finance.yahoo.com - March 20 at 4:10 PM
Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with AcromegalyChiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly
finance.yahoo.com - March 16 at 10:00 AM
Want To Invest In Chiasma Inc (NASDAQ:CHMA)? Here’s How It Performed LatelyWant To Invest In Chiasma Inc (NASDAQ:CHMA)? Here’s How It Performed Lately
finance.yahoo.com - March 14 at 10:44 AM
Chiasma (CHMA) Set to Announce Earnings on WednesdayChiasma (CHMA) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:32 AM
Chiasma to Present at the Cowen and Company 38th Annual Health Care ConferenceChiasma to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 9:57 AM
Chiasma Honors Patients, Researchers for Rare Disease Day 2018Chiasma Honors Patients, Researchers for Rare Disease Day 2018
finance.yahoo.com - February 28 at 9:35 AM
Contrasting Syndax Pharmaceuticals (SNDX) & Chiasma (CHMA)Contrasting Syndax Pharmaceuticals (SNDX) & Chiasma (CHMA)
www.americanbankingnews.com - February 10 at 11:10 PM
Sonoma Pharmaceuticals (SNOA) vs. Chiasma (CHMA) Head-To-Head ContrastSonoma Pharmaceuticals (SNOA) vs. Chiasma (CHMA) Head-To-Head Contrast
www.americanbankingnews.com - January 20 at 11:28 AM
Zacks: Chiasma Inc (CHMA) Receives Average Recommendation of "Strong Sell" from BrokeragesZacks: Chiasma Inc (CHMA) Receives Average Recommendation of "Strong Sell" from Brokerages
www.americanbankingnews.com - January 16 at 1:10 PM
Chiasma Reports on Significant Progress Made During 2017Chiasma Reports on Significant Progress Made During 2017
finance.yahoo.com - January 8 at 9:48 AM
Chiasma, Inc. (CHMA) Receives Average Recommendation of "Strong Sell" from Analysts Chiasma, Inc. (CHMA) Receives Average Recommendation of "Strong Sell" from Analysts
www.americanbankingnews.com - December 16 at 11:10 PM
Critical Analysis: Chiasma (CHMA) vs. Catalyst Biosciences (CBIO)Critical Analysis: Chiasma (CHMA) vs. Catalyst Biosciences (CBIO)
www.americanbankingnews.com - December 1 at 11:16 AM
Zacks: Chiasma, Inc. (CHMA) Given Average Rating of "Strong Sell" by BrokeragesZacks: Chiasma, Inc. (CHMA) Given Average Rating of "Strong Sell" by Brokerages
www.americanbankingnews.com - November 24 at 11:16 AM
BRIEF-Chiasma Q3 loss per share $0.28BRIEF-Chiasma Q3 loss per share $0.28
www.reuters.com - November 11 at 11:31 AM
Chiasma Reports Third Quarter 2017 ResultsChiasma Reports Third Quarter 2017 Results
finance.yahoo.com - November 9 at 8:02 PM
Chiasma reports 3Q lossChiasma reports 3Q loss
finance.yahoo.com - November 9 at 8:02 PM
Is Chiasma Inc’s (CHMA) CEO Pay Fair?Is Chiasma Inc’s (CHMA) CEO Pay Fair?
finance.yahoo.com - November 7 at 8:09 PM
Chiasma, Inc. (CHMA) Scheduled to Post Quarterly Earnings on TuesdayChiasma, Inc. (CHMA) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
Head-To-Head Survey: Chiasma (CHMA) & VIVUS (VVUS)Head-To-Head Survey: Chiasma (CHMA) & VIVUS (VVUS)
www.americanbankingnews.com - October 25 at 4:27 AM
Chiasma (CHMA) vs. Its Competitors Financial SurveyChiasma (CHMA) vs. Its Competitors Financial Survey
www.americanbankingnews.com - October 23 at 8:30 AM
Comparing Chiasma (CHMA) & The CompetitionComparing Chiasma (CHMA) & The Competition
www.americanbankingnews.com - October 23 at 2:08 AM
Head-To-Head Comparison: Chiasma (CHMA) versus Its PeersHead-To-Head Comparison: Chiasma (CHMA) versus Its Peers
www.americanbankingnews.com - October 17 at 4:08 AM
Financial Comparison: Opiant Pharmaceuticals (OPNT) versus Chiasma (CHMA)Financial Comparison: Opiant Pharmaceuticals (OPNT) versus Chiasma (CHMA)
www.americanbankingnews.com - October 15 at 8:28 PM
Chiasma, Inc. (CHMA) Sees Significant Drop in Short InterestChiasma, Inc. (CHMA) Sees Significant Drop in Short Interest
www.americanbankingnews.com - October 15 at 2:20 AM
BioMarin Pharmaceutical (BMRN) vs. Chiasma (CHMA) Head-To-Head ContrastBioMarin Pharmaceutical (BMRN) vs. Chiasma (CHMA) Head-To-Head Contrast
www.americanbankingnews.com - October 13 at 12:26 AM
Critical Analysis: Chiasma (CHMA) & KalVista Pharmaceuticals (KALV)Critical Analysis: Chiasma (CHMA) & KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - October 12 at 2:32 PM
AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls BackAERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back
www.rttnews.com - October 11 at 11:40 PM
Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with AcromegalyChiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly
finance.yahoo.com - October 2 at 4:44 PM
Chiasma, Inc. (CHMA) Reports First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide ... - StreetInsider.comChiasma, Inc. (CHMA) Reports First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide ... - StreetInsider.com
www.streetinsider.com - September 29 at 8:17 AM
Phase 3 MPOWERED Trial Surpasses 50% Patients RandomizedPhase 3 MPOWERED Trial Surpasses 50% Patients Randomized
www.thestreet.com - September 28 at 10:10 PM
Reviewing Chiasma (CHMA) and Its PeersReviewing Chiasma (CHMA) and Its Peers
www.americanbankingnews.com - September 26 at 8:22 PM
Chiasma, Inc. (CHMA) Director Scott Minick Acquires 15,000 SharesChiasma, Inc. (CHMA) Director Scott Minick Acquires 15,000 Shares
www.americanbankingnews.com - September 22 at 8:38 PM
Chiasma, Inc. (CHMA) Director Buys $59,250.00 in StockChiasma, Inc. (CHMA) Director Buys $59,250.00 in Stock
www.americanbankingnews.com - September 22 at 8:38 PM
Critical Comparison: Chiasma (CHMA) versus ChemoCentryx (CCXI)Critical Comparison: Chiasma (CHMA) versus ChemoCentryx (CCXI)
www.americanbankingnews.com - September 8 at 6:10 AM
Head-To-Head Survey: Chiasma (CHMA) and Vitae Pharmaceuticals (VTAE)Head-To-Head Survey: Chiasma (CHMA) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - August 23 at 12:20 PM
Chiasma, Inc. (CHMA) Announces Agreement with FDA Under SPA for New Phase 3 Clinical Trial of Octreotide Capsules in AcromegalyChiasma, Inc. (CHMA) Announces Agreement with FDA Under SPA for New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
www.streetinsider.com - August 12 at 4:43 PM
Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in AcromegalyChiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
finance.yahoo.com - August 10 at 6:25 PM
Chiasma Reports Second Quarter 2017 ResultsChiasma Reports Second Quarter 2017 Results
finance.yahoo.com - August 10 at 6:25 PM
Chiasma reports 2Q lossChiasma reports 2Q loss
finance.yahoo.com - August 10 at 6:25 PM
Chiasma, Inc. (NASDAQ:CHMA) Set to Announce Quarterly Earnings on TuesdayChiasma, Inc. (NASDAQ:CHMA) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM
Head to Head Review: Alimera Sciences (ALIM) vs. Chiasma (NASDAQ:CHMA)Head to Head Review: Alimera Sciences (ALIM) vs. Chiasma (NASDAQ:CHMA)
www.americanbankingnews.com - July 10 at 12:14 AM
Chiasma (CHMA) Announces Poster Presentation at ENDO - StreetInsider.comChiasma (CHMA) Announces Poster Presentation at ENDO - StreetInsider.com
www.streetinsider.com - March 31 at 2:43 AM
Chiasma (CHMA) Announces Poster Presentation at ENDOChiasma (CHMA) Announces Poster Presentation at ENDO
www.streetinsider.com - March 30 at 9:43 PM
Chiasma Reports Fourth Quarter and Year End 2016 ResultsChiasma Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 16 at 10:37 PM
CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsCHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 10:37 PM
Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017
us.rd.yahoo.com - January 9 at 5:25 PM

SEC Filings

Chiasma (NASDAQ:CHMA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Chiasma (NASDAQ:CHMA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Chiasma (NASDAQ CHMA) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.